General
Preferred name
SULFASALAZINE
Synonyms
NSC 667219 ()
Azulfidine ()
SULFASALAZINE599-79-1 ()
Azulfidine, Salazopyrin, Sulphasalazine, NSC 667219 ()
Sulfasalazine (NSC 667219) ()
Benzosulfa ()
Azulfidine EN-Tabs ()
Sulfasalazinum ()
Salazosulfapyridine ()
NSC-667219 ()
Salazopyrin ()
Sulfasalazopyridine ()
S.A.S.-500 ()
Salazopyrin E.C. ()
Salazopyrin-En ()
Ucine ()
Salicylazosulfapyridine ()
NSC-203730 ()
SAS-500 ()
Sulphasalazine ()
Colizine ()
Sulfasalazina ()
P&D ID
PD001744
CAS
599-79-1
Tags
available
drug
Approved by
FDA
First approval
1950
Drug Status
approved
Max Phase
4.0
Drug indication
Ankylosing spondylitis
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
DESCRIPTION
Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress NF-¦ÊB activity. Sulfasalazine is a type 1 ferroptosis inducer[1][2][3][4].
DESCRIPTION
Sulfasalazine (Azulfidine) is a synthetic salicylic acid derivative with affinity for elastin-containing connective tissues and formulated as a prodrug. Sulfasalazine induces iron death and inhibits NF-??B, TGF-?? and COX-2.
DESCRIPTION
gp130 inhibitor; blocks cytokine-triggered gp130 signaling
(Tocris Bioactive Compound Library)
DESCRIPTION
Inhibitor of NF-kappaB activation; also inhibits SXC
(Tocriscreen Plus)
DESCRIPTION
Sulfasalazine (Azulfidine) is a synthetic salicylic acid derivative with affinity for elastin-containing connective tissues and formulated as a prodrug. Sulfasalazine induces iron death and inhibits NF-κB, TGF-β and COX-2.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
22
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
JUMP-Target 1 Compound Set
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
41
Molecular Weight
398.07
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
3
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
3
cLogP
3.7
TPSA
141.31
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.54
Structural alerts
1
azo_A(324)
[#7;!R]=[#7]
PAINS Family A
Related compounds
Custom attributes
(extracted from source data)
Target Type
Cell Biology
Target
NF-¦ÊB
COX,NF-??
ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1
IKK inhibitor
PLA2G1B
antibiotic
Bacterial
Ferroptosis
Apoptosis related,Autophagy,COX,Ferroptosis,Immunology & Inflammation related,NF-¦ÊB,TGF-beta/Smad
COX-1
COX-2
Pathway
Apoptosis
Autophagy
Immunology/Inflammation
Microbiology/virology
Neuroscience
NF-κB
NF-??
NF-¦ªb
Anti-infection
Primary Target
NF-?B and I?B
MOA
Inhibitor
COX inhibitor
NF-¦ÊB inhibitor
cyclooxygenase inhibitor
Indication
ulcerative colitis
Source data
